SEEL Seelos Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: SEEL

Price (delayed)

$0.3393

Market cap

$4.64M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$7.73

Enterprise value

$15.87M

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous ...

Highlights
The EPS has soared by 63% YoY and by 40% from the previous quarter
The net income has grown by 48% YoY and by 26% from the previous quarter
The company's quick ratio has shrunk by 84% YoY but it rose by 25% QoQ
The equity has contracted by 10% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://seelostherapeutics.com
Peers: OMER OMGA

Key stats

What are the main financial stats of SEEL
Market
Shares outstanding
13.68M
Market cap
$4.64M
Enterprise value
$15.87M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
0.75
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.21
Earnings
Revenue
$2.2M
EBIT
-$37.81M
EBITDA
-$37.75M
Free cash flow
-$23.91M
Per share
EPS
-$7.73
Free cash flow per share
-$4.88
Book value per share
-$6.23
Revenue per share
$0.45
TBVPS
$1.11
Balance sheet
Total assets
$5.42M
Total liabilities
$38.93M
Debt
$14.23M
Equity
-$33.51M
Working capital
-$33.53M
Liquidity
Debt to equity
-0.42
Current ratio
0.14
Quick ratio
0.1
Net debt/EBITDA
-0.3
Margins
EBITDA margin
-1,713.6%
Gross margin
100%
Net margin
-1,719.6%
Operating margin
-1,838.4%
Efficiency
Return on assets
-321.3%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
N/A
Return on sales
-1,716.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

SEEL stock price

How has the Seelos Therapeutics stock price performed over time
Intraday
2.82%
1 week
17%
1 month
-39.54%
1 year
-98.49%
YTD
-75.59%
QTD
-42.59%

Financial performance

How have Seelos Therapeutics's revenue and profit performed over time
Revenue
$2.2M
Gross profit
$2.2M
Operating income
-$40.5M
Net income
-$37.88M
Gross margin
100%
Net margin
-1,719.6%
The company's net margin rose by 48% QoQ
The net income has grown by 48% YoY and by 26% from the previous quarter
SEEL's operating margin is up by 44% QoQ
The operating income has grown by 43% YoY and by 20% from the previous quarter

Growth

What is Seelos Therapeutics's growth rate over time

Valuation

What is Seelos Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
0.75
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.21
The EPS has soared by 63% YoY and by 40% from the previous quarter
The equity has contracted by 10% from the previous quarter
SEEL's P/S is 99% below its last 4 quarters average of 63.3
The revenue has increased by 42% from the previous quarter

Efficiency

How efficient is Seelos Therapeutics business performance
The return on assets has dropped by 104% year-on-year
The ROS has grown by 48% from the previous quarter

Dividends

What is SEEL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SEEL.

Financial health

How did Seelos Therapeutics financials performed over time
The total assets is 86% smaller than the total liabilities
The current ratio has shrunk by 84% YoY and by 22% QoQ
The company's quick ratio has shrunk by 84% YoY but it rose by 25% QoQ
The company's debt is 142% higher than its equity
The debt to equity has soared by 78% YoY and by 25% QoQ
The company's debt fell by 29% YoY and by 16% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.